Celldex Therapeutics, Inc. 8-KCurrent Reports (8-K / ad hoc)

Financial Statements

Item 8.01. Other Events. On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of Barzolvolimab in chronic spontaneous urticaria (CSU). A copy of this press release is attached hereto as Exhibit 99.1 hereto and is incorporated by reference herein.